An observational study in Pacemaker, Artificial and Cardiomyopathies, sponsored by The Guthrie Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-22.
Sponsored by The Guthrie Clinic · Observational
Among 230 studies in Cardiomyopathies with a site in United States — 57 open to participants now, 68 under way, 6 of them phase 3. Cardiomyopathies · United States.
Among the 230 studies in Cardiomyopathies with a site in United States, this one is the 51st largest by enrollment of the 96 observational ones that give a count, is one of 4 that started in 2017, is one of 97 observational ones, and was the 140th registered.
553 studies on the registry are indexed under Cardiomyopathies; 152 are open to participants now.
This study's enrollment of 153 is below the median of 200 across 263 observational studies indexed under Cardiomyopathies.
Browse Cardiomyopathies studies →57 of the 230 studies in Cardiomyopathies with a site in United States are open now.
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 116 Cardiomyopathies studies recruiting now, 71 (61%) set no upper age limit and 17 (15%) stop at 75 or younger; 36 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 32 · Phase 3 20 · Phase 4 13
First in 1996; this study’s year is marked. 4 started in 2017.
Median enrollment 42 across the 132 interventional studies, 160 across the 96 observational. Of the 139 that completed or were terminated, 65 (47%) have results posted.
72 of 230 have an industry lead sponsor. The 10 most frequent:
The Guthrie Clinic is the lead sponsor of 26 studies on the registry; none are open to participants now.
The Guthrie Clinic has 1 study filed under Cardiomyopathies — fewer than ten, so there is no comparison to draw.
17 of the studies in Cardiomyopathies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06109181Lexeo TherapeuticsGene Therapy for ACM Due to a PKP2 Pathogenic Variant | 2026-12 |
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT04843371Tulane UniversityPPG to Predict Ejection Fraction and Other Echographic Data in the General Population | 2026-12 |
| NCT02855554Medical University of South CarolinaQuantitative Cardiac Parametric Mapping | 2026-12 |
| NCT03534726University of PennsylvaniaEdema and Fibrosis CMR Imaging in Cardiomyopathy | 2026-12-31 |
Among the 230 studies in Cardiomyopathies with a site in United States, from their registry updates:
The purpose of this study is to collect a saliva sample from patients with a pacemaker to study genes involved in cardiomyopathy, a condition where the heart muscle is abnormal.
DNA will be extracted from the saliva to test for changes in genes related to cardiomyopathy.
Patients seen at Robert Packer Hospital, Sayre, PA
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Saliva sample for genetic testing from subjects who developed cardiomyopathy
Other: Saliva sample
Saliva sample for genetic testing from subjects who do not have cariomyopathy
Other: Saliva sample
Extract sample of saliva only once
Number of participants with genotype frequency
Number of participants with genotype frequency based on genetic testing of saliva samples
Time frame: through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2017 to primary completion in Jun 2025, 92 months.
Of 119 non-industry observational studies under Cardiomyopathies, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 34. This study's 92 months is close to that.
Counting every sponsor, half of 140 studies reached it within 83 months; a quarter within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Guthrie Clinic